Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Interleukin 2 and psoriasis.

R E Lee¹, A A Gaspari, M T Lotze

¹Surgery Branch, National Cancer Institute, Bethesda, Md 20892.

Archives of Dermatology

|December 1, 1988

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Diagnostic dilemmas of Titanium Hypersensitivity in patients with medical implants: a case series.

European annals of allergy and clinical immunology·2020

Same author

Cross-elicitation responses to 2-methoxymethyl-p-phenylenediamine in p-phenylenediamine highly allergic volunteers using allergy alert test: the Italian experience.

European annals of allergy and clinical immunology·2019

Same author

Effects of TIO NICKEL in patients with ACD and SNAS: experience on 700 patients in Italy.

Journal of the European Academy of Dermatology and Venereology : JEADV·2016

Same author

A case of hypersensitivity to progesterone presenting as an eczematous eruption.

European annals of allergy and clinical immunology·2016

Same author

Resolution of septic shock in a patient with myelomeningocele (spina bifida) complicated with deforming Elephantiasis Nostras Verrucosa.

Journal of the European Academy of Dermatology and Venereology : JEADV·2015

Same author

Dopaminergic receptors in the human skin.

Journal of biological regulators and homeostatic agents·2012

High-dose interleukin 2 (IL-2) immunotherapy can trigger psoriasis flares in patients with metastatic cancer. However, these skin reactions did not impede cancer treatment and responded well to topical therapies.

Area of Science:

Oncology
Immunology
Dermatology

Background:

High-dose interleukin 2 (IL-2) and lymphokine-activated killer (LAK) cell immunotherapy are established treatments for metastatic cancers.
Common side effects include skin reactions like erythema, pruritus, and desquamation.

Observation:

Three patients with a history of psoriasis received IL-2 based immunotherapy for metastatic renal cell carcinoma.
Two patients experienced an erythrodermic exacerbation of their psoriasis, while one had a localized flare.

Findings:

Histologic examination revealed psoriasiform changes, epidermal spongiosis, and a perivascular mononuclear cell infiltrate in affected skin.
Topical treatments successfully induced remission of the psoriatic exacerbations in all three patients.

Related Experiment Videos

Implications:

Psoriatic exacerbations during IL-2 immunotherapy do not negatively impact the antitumor response.
These skin reactions should not preclude patients from receiving potentially life-saving immunotherapy.